����ʡ��ҽԺ

��ժҪ�� ëù����һ����Ϯ��Ⱦ���������Ҫ���������߹��������ƵĻ��ߣ������ʸߡ�ëù�������Ʒ����ܶ࣬��������崴������Ч�Ŀ����ҩ������Ҫ�����Ʋ��ԡ�����ëù���Ŀ����ҩ���ж�ϩ�ࡢ���ࡢ����ù�����Լ������ҩ���������ƣ���������Ч��ҩ��Ϊ��ϩ�࣬��������࿹���������Ҫ������ҩ�в�ɳ�������⣬����������µ�����ҩ��ɳ����Ҳ������ëù��������ù�ص�������ëù��Ч���ѣ����������������Ӧ����Эͬ�������á������ϼ��͸�ѹ������Ч�д��о�������ù��B֬������Ϊ��ѡ���ƣ�����ɳ�����Ǻ���ǰ��������ëùҩ����ڻ����������������ڽ���ëù���������ʡ�

Zhang Siping Department of Dermatology, Anhui Provincial Hospital, Hefei 230001, China Corresponding author: Zhang Siping, Email: zh_siping@126.com ��Abstract�� Mucormycosis is an invasive fungal infection with high mortality, and mainly occurs in immunocompromised patients. Many treatments are available for mucormycosis, and surgical debridement in combination with antifungal agents is the main therapeutic strategy. Polyenes, azoles and echinocandins, alone or in combination, are used for the treatment of mucormycosis. The most effective antifungal agent is polyenes, followed by azoles which mainly include posaconazole. In addition, voriconazole and new azoles such as isavuconazole are also applied in the treatment of mucormycosis. The efficacy of echinocandins alone is poor, but its combination with other antifungal agents shows good synergistic effects. Further studies are needed to evaluate the therapeutic effects of iron chelating agents and hyperbaric oxygen. Amphotericin B lipid usually serves as the preferred treatment, and posaconazole is regarded as a promising alternative. Early active and combined treatment is helpful in decreasing the mortality of mucormycosis.